A drug used to treat HIV has proved 100 percent effective at preventing infection in a major clinical trial, researchers say.
The trial involved over 5,000 women and girls in South Africa and Uganda. Some were given injections of the drug lenacapavir every six months, others took daily pills.
None of those receiving the injections contracted HIV, compared with 55 infections in the pill groups.
The study's authors say the findings, published in the New England Journal of Medicine, are "a major breakthrough".
Lenacapavir is currently approved to treat HIV but getting regulatory approval for use as prevention could massively expand access, they argue.
Twice-yearly dosing would be much more convenient than daily pills and could significantly boost uptake and adherence to pre-exposure prophylaxis (PrEP).
Linda-Gail Bekker (MD), from the University of Cape Town, said the results showed lenacapavir could offer "a highly effective, tolerable and discreet choice" for prevention.
The manufacturer, Gilead Sciences, hopes data from this and further trials will support regulatory approval for use as PrEP across different populations.
Access issues will need addressing, as current HIV drugs can be prohibitively expensive. But experts believe generic competition could drive costs down to as little as 40 dollars per person annually.
Wider availability of long-acting options like lenacapavir injections could revolutionise HIV prevention, supporters argue.
